#compounded

GLP-1 medications like Ozempic and Wegovy can help PCOS because the syndrome is driven by insulin resistance, and these drugs improve insulin sensitivity, drive weight loss, and in trials restored menstrual regularity and raised natural-pregnancy rates. But here is the catch almost no one explains: PCOS by itself is NOT an FDA-approved reason to prescribe any GLP-1, so insurance and brand savings cards hinge on your BMI and comorbidities, not your PCOS diagnosis. This guide covers the trial signal, why insurance denies PCOS-only requests, the BMI rules behind savings cards, and the cheaper cash-pay paths if you do not qualify.

FDA resolved the semaglutide shortage on February 21, 2025 and ended temporary shortage-based enforcement discretion on April 22 for 503A pharmacies and May 22 for 503B facilities. This guide separates those dates from FDA's pending 503B bulk-list proposal and compares paths to discuss with a prescriber.

Verified May 8, 2026, Updated August 12, 2026: On April 30, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use based on clinical need. The public comment period closed July 30, 2026 (Docket FDA-2018-N-3240; extension notice 91 FR 38719, published June 26, 2026). Days before that deadline, the Pharmacy Compounding Advisory Committee voted on seven peptides nominated for the separate 503A list and recommended six. Those votes are advisory, not FDA approval, and the 503B proposal was not final when last checked.

Verified May 2026: Tirzepatide starts at 2.5 mg once weekly (non-therapeutic starter dose), escalates by 2.5 mg every 4 weeks to a maximum of 15 mg once weekly. Full escalation takes 20 weeks. At 72 weeks, the 15 mg dose produced 20.9% body weight loss in SURMOUNT-1, equivalent to roughly 47 lbs for a 225-lb person. The 5 mg and 10 mg doses are also valid long-term maintenance doses (15% and 19.5% weight loss respectively). Same dosing schedule applies to Zepbound, Mounjaro, and compounded tirzepatide.

Verified August 7, 2026: NovoCare lists the brand-name Wegovy pen at $199/mo for the first two low-dose fills, then $349/mo at standard strengths ($399 for HD) and the oral pill from $149/mo, dose-dependent; Zepbound starts at $299/mo via LillyDirect. Compounded offerings may advertise lower prices but require product- and prescription-specific regulatory review.

Verified August 2026: Tirzepatide prices include $149/mo via Gala on a yearly microdose plan ($169/mo for 3 months), $299/mo via LillyDirect (brand Zepbound 2.5mg vial), $399 for the 5mg vial, $449 for 7.5mg and higher doses when refill conditions are met, $25/mo with an eligible Zepbound savings card, or $1,086/mo retail list price. Full price breakdown with 54 tracked providers.

Tirzepatide's shortage was resolved in October 2024 and shortage-based enforcement discretion ended in early 2025. This guide compares advertised compounded prices with brand Zepbound and explains why legality, formulation, and safety cannot be inferred from availability alone.

A source-bounded guide to FDA warning letters involving compounded GLP-1 marketing, labeling, and manufacturing. Our linked tracker is finite and does not certify safety or compliance.